Berberine Activates Key Hair Growth Pathway by Blocking Axin2 Protein
A natural compound used in traditional Chinese medicine may offer a new treatment for androgenetic alopecia by activating the Wnt/β-catenin signaling pathway.
Summary
Researchers from Fudan University found that berberine (BBR), a plant-derived compound long used in Chinese medicine, promotes hair growth by targeting Axin2 and activating the Wnt/β-catenin signaling pathway. Using human dermal papilla cells, hair follicle models, and a mouse depilation model, the team showed BBR enhanced cell proliferation, extended the hair growth (anagen) phase, and reversed miniaturization of hair follicles. Molecular docking and gene knockdown experiments confirmed Axin2 as a key target. Notably, androgenetic alopecia often co-occurs with metabolic conditions like insulin resistance and PCOS — conditions berberine already treats clinically — suggesting a dual-benefit potential for affected patients.
Detailed Summary
Androgenetic alopecia (AGA) is the most prevalent form of hair loss globally, affecting millions and carrying significant psychological and quality-of-life burdens. Importantly, AGA frequently co-occurs with metabolic disorders including insulin resistance, polycystic ovary syndrome (PCOS), and cardiovascular disease — comorbidities that berberine (BBR) already addresses in clinical practice in China. This convergence makes BBR an especially attractive candidate for AGA therapy.
Researchers at Fudan University's Huashan Hospital investigated whether BBR could directly promote hair growth and clarify its mechanism. They used human dermal papilla cells (hDPCs), both normal and miniaturized hair follicle organ cultures, and a mouse depilation-induced hair regrowth model. Network pharmacology, RNA sequencing, molecular docking, cell transfection, and reporter gene assays were employed to map the mechanistic pathway.
BBR consistently enhanced hDPC proliferation, increased the length of both normal and miniaturized hair follicles in vitro, and prolonged the anagen (active growth) phase. In mice, topical BBR treatment accelerated visible hair regrowth and delayed transition to the catagen (regression) phase, confirmed by histological analysis. These effects were linked to cell cycle regulation downstream of Wnt/β-catenin signaling activation.
Mechanistic experiments identified Axin2 — a negative regulator of the Wnt pathway — as a direct molecular target of BBR. Molecular docking supported a binding interaction, and Axin2 knockdown experiments reduced BBR's ability to stimulate hDPC proliferation, confirming its centrality to BBR's mechanism of action.
While findings are promising, the study is preclinical and limited to cellular and animal models. Clinical trials are needed to establish efficacy and safety in humans. The optimal delivery method and concentration for topical use also remain to be determined in human studies.
Key Findings
- Berberine extended anagen phase and increased hair follicle length in both normal and miniaturized follicle models.
- Topical BBR significantly accelerated hair regrowth in a mouse depilation model confirmed by histology.
- BBR targets Axin2, a Wnt pathway inhibitor, activating β-catenin signaling to drive dermal papilla cell proliferation.
- Axin2 gene knockdown blunted BBR's proliferative effect, confirming it as the key mechanistic target.
- BBR's dual activity against AGA and its common metabolic comorbidities positions it as a uniquely promising therapeutic candidate.
Methodology
The study combined in vitro models (human dermal papilla cells and hair follicle organ cultures) with an in vivo mouse depilation model. Mechanistic investigation used network pharmacology, RNA sequencing, molecular docking, cell transfection, reporter gene assays, and immunohistochemistry. Axin2 knockdown experiments were used to confirm target specificity.
Study Limitations
This study is entirely preclinical — results in cell cultures and mouse models may not directly translate to humans. Clinical trials are needed to confirm efficacy, determine optimal dosing and delivery routes, and assess long-term safety for hair loss indications. The abstract does not detail whether BBR was applied topically or systemically in all models.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.